Dr. Anca Maria Barbu is a Laryngeal Surgeon at the MGH Center for Laryngeal Surgery and Voice Rehabilitation who specializes in the care of patients with voice problems, papillomatosis, vocal paralysis, and cancers of the larynx.
BiographyDr. Anca Maria Barbu graduated with honors from the University of California, Los Angeles with degrees in European Studies and Physiological Sciences. She earned her MD from Drexel University College of Medicine in Philadelphia and received residency training in both General Surgery and Otolaryngology at Case Western Reserve University Hospitals in Cleveland, Ohio. After graduation, she remained on faculty at Case as a full-time surgeon in the Department of Otolaryngology- Head & Neck Surgery before moving to Boston for her fellowship at the Massachusetts General Hospital (MGH) Voice Center.
During her fellowship, Dr. Barbu completed a two-year research and clinical program with Drs. Zeitels and Burns during which she assisted in the Avastin (bevacizumab) prospective clinical trial for recurrent respiratory papillomatosis at the MGH Voice Center, in conjunction with the MGH Translational Medicine Group and the Food and Drug Administration (FDA). Her clinical work included training in advanced techniques in endoscopic treatment of laryngeal cancer, framework surgery for vocal cord paralysis, management of laryngeal stenosis, and phonomicrosurgery for benign laryngeal lesions in professional voice users. In addition, she is trained in state-of-the-art office-based procedures, which are designed to eliminate the need for general anesthesia and the operating room in the management of potentially chronic laryngeal disorders such as papillomatosis and dysplasia. She is board-certified in Otolaryngology-Head & Neck Surgery and teaches at Harvard Medical School.
Dr. Barbu has joined the MGH Voice Center as the first woman laryngeal surgeon in the Division. She is pleased to offer compassionate and cutting-edge clinical care while also pursuing research in the advancement and innovation of the field of laryngeal surgery.
ResearchDr. Barbu's research interests include treatment of patients with recurrent respiratory papillomatosis (RRP) in both the office and OR setting. She has collaborated with Drs. Steven Zeitels on advancing therapy for RRP via the only prospective FDA-approved study for the use of bevacizumab (Avastin) in papillomatosis. Her publications also include advancing treatment of laryngeal cancer and vocal cord paralysis.